VISCHER advises Versantis on its sale to Gentif

Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit.

With this acquisition, Genfit intends to expand its product portfolio with a Phase 2 ready programme based on first-in-class scanning liposome technology, a paediatric programme focused on urea cycle disorder or an early-stage programme focused on hepatic encephalopathy. The terms of the agreement include a payment of CHF 40 million, a total of CHF 65 million of potential additional payments based on the success of clinical and regulatory milestones, and one-third of the net proceeds from the potential sale of a priority review voucher, if granted by the FDA.

VISCHER is assisting Versantis. The team is led by partner Matthias Staehelin (pictured right) with partner Christian Wyss (pictured left), Vincent Reardon (managing associate) and associate Pauline Pfirter (all corporate) as well as partner Christoph Niederer and associate Veysel Oruclar (both tax).

VISCHER advises Versantis on its sale to Gentif


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram